Active ingredient
- trastuzumab
- pertuzumab
Legal Category
POM: Prescription only medicine
POM: Prescription only medicine
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.
Below is a text only representation of the Patient Information Leaflet. The original leaflet can be viewed using the link above.
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PLGB 00031/0921.
Phesgo 600 mg/600 mg, 1200 mg/600 mg solution for injection
Package leaflet: Information for the user
Phesgo 600 mg/600 mg solution for injection
Phesgo 1200 mg/600 mg solution for injection
pertuzumab/trastuzumab
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
What is in this leaflet
1. What Phesgo is and what it is used for
2. What you need to know before you are given Phesgo
3. How you are given Phesgo
4. Possible side effects
5. How to store Phesgo
6. Contents of the pack and other information
1. What Phesgo is and what it is used for
Phesgo is a cancer medicine that contains two active substances: pertuzumab and trastuzumab.
Phesgo is available in two different strengths. See section 6 for more information.
Phesgo is used to treat adult patients with breast cancer that is of the “HER2-positive” type – your doctor will test you for this. It can be used when:
As part of your treatment with Phesgo you will also receive other medicines called chemotherapy. Information about these medicines is described in separate package leaflets. Ask your doctor, pharmacist or nurse to give you information about these other medicines.
2. What you need to know before you are given Phesgo
You must not be given Phesgo
If you are not sure, talk to your doctor, pharmacist or nurse before you are given Phesgo
Warnings and precautions
Heart problems
Treatment with Phesgo may affect the heart. Talk to your doctor, pharmacist or nurse before you are given Phesgo if:
If any of the above applies to you (or you are not sure), talk to your doctor or nurse before you are given Phesgo. See section 4 “Serious side effects” for more details about signs of heart problems to look out for.
Injection reactions
A reaction to the injection can happen. These are allergic reactions and can be severe.
If you get any serious reaction, your doctor may stop treatment with Phesgo. See section 4 ‘‘Serious side effects’’ for more details about injection related reactions to look out for during the injection and thereafter.
Your doctor or nurse will check for side effects during your injection and for:
If you get any serious reaction, your doctor may stop treatment with Phesgo.
Low levels of white blood cells and fever (Febrile neutropenia)
When Phesgo is given with chemotherapy medicines, the number of white blood cells may drop and fever may develop. If you have inflammation of the digestive tract (e.g. sore mouth or diarrhoea) you may be more likely to develop this side effect. If the fever persists for several days, this may be a sign of worsening of your condition and you should contact your physician.
Diarrhoea
Treatment with Phesgo may cause severe diarrhoea. Patients over 65 years of age have a higher risk of diarrhoea compared with patients younger than 65 years of age. If you get severe diarrhoea during your cancer treatment, your doctor may give you medicines to control diarrhoea. Your doctor may also stop your treatment with Phesgo until the diarrhoea is under control.
Children and adolescents
Phesgo should not be given to patients under the age of 18 years because there is no information on how it works in this age group.
Elderly patients over 65
Patients over 65 years of age are more likely to get side effects such as reduced appetite, decrease in the number of red blood cells, weight loss, tiredness, loss or altered taste, weakness, numbness, tingling or prickling sensations mainly affecting the feet and legs and diarrhoea, compared to patients younger than 65 years of age.
Other medicines and Phesgo
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.
Pregnancy, breast-feeding and contraception
Before starting treatment, you must tell your doctor, pharmacist or nurse if you are pregnant or breast-feeding, or if you think you may be pregnant or are planning to have a baby. They will discuss with you the benefits and risks for you and your baby of taking Phesgo while you are pregnant.
Driving and using machines
Phesgo may affect your ability to drive or operate machines. If during treatment you experience symptoms, such as feeling dizzy, chills, fever or any injection or allergic reactions as described in section 4, you should not drive or use machines until these symptoms disappear.
Phesgo contains Sodium
Phesgo contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially sodium-free.
3. How you are given Phesgo
Phesgo will be given to you by a doctor or nurse in a hospital or clinic as an injection under your skin (subcutaneous injection).
Start of the treatment (loading dose)
Subsequent injections (maintenance doses), which will be given if the first injection have not caused severe side effects:
For further information on loading and maintenance dose see section 6.
For further information on dosing of chemotherapy (which can cause side effects as well), please read the package leaflet for these medicines. If you have questions about them, please ask your doctor, pharmacist or nurse.
If you forget to have Phesgo
If you miss your appointment to have Phesgo make another appointment as soon as possible. Depending on how much time passed between the two visits, your doctor will decide which strength of Phesgo to give you.
If you stop having Phesgo
Do not stop your treatment with this medicine without talking to your doctor first. It is important that you are given the full course of injections at the right time every three weeks. This helps your medicine work as well as it can.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects
Tell a doctor or nurse straight away, if you notice any of the following side effects:
Tell a doctor or nurse straight away, if you notice any of the side effects above.
Other side effects
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
If you get any of the side effects above, talk to your doctor, nurse or pharmacist.
If you get any of the above after treatment with Phesgo has been stopped, you should get in touch with your doctor immediately and say that you have previously been treated with Phesgo.
Some of the side effects which you get may be due to your breast cancer. If you are given Phesgo with chemotherapy at the same time, some side effects may also be due to these other medicines.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.
United Kingdom
or search for MHRA Yellow Card in the Google Play or Apple App Store
5. How to store Phesgo
Phesgo will be stored by the health professionals at the hospital or clinic. The storage details are as follows:
6. Contents of the pack and other information
What Phesgo contains
The active substances are pertuzumab and trastuzumab.
The other ingredients are vorhyaluronidase alfa, L-histidine, L-histidine hydrochloride monohydrate, α,α-trehalose dihydrate, sucrose, L-methionine, polysorbate 20 and water for injections (see section 2 “Phesgo contains sodium”).
What Phesgo looks like and contents of the pack
Phesgo is a solution for injection. It is a clear to opalescent solution, colourless to slightly brown supplied in a glass vial. Each pack contains one vial with either 10 mL or 15 mL solution.
Marketing Authorisation Holder and Manufacturer
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
This leaflet was last revised in January 2022
gb-pil-phesgo-clean-220126-600mg-1200mg-inj
Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire, AL7 1TW
+44 (0)1707 366 000
+44 (0)800 328 1629
+44 (0)800 731 5711
+44 (0)1707 338 297
+44 (0)1707 384555